Articles Tagged With: efficacy
-
Vonoprazan Fumarate Tablets (Voquezna)
The U.S. Food and Drug Administration has approved vonoprazan for the treatment of all grades of erosive esophagitis. Vonoprazan is a potassium-competitive acid blocker that originally was approved in 2022 for use in combination with amoxicillin or with amoxicillin and clarithromycin for the treatment of Helicobactor pylori infection.
-
Atorvastatin vs. Rosuvastatin in Patients with Coronary Artery Disease
A large trial of moderate doses of rosuvastatin vs. atorvastatin in patients with coronary artery disease has shown that both drugs are equivalent at reducing major adverse cardiovascular and cerebral events, but rosuvastatin is associated with higher rates of new- onset diabetes and cataract surgery.
-
Oral Contraception and Obesity
This study was a re-analysis of drospirenone 4 mg Phase III efficacy trials comparing 590 non-obese and 325 obese patients who showed equivalent pregnancy rates with Pearl Indices of 3.0 (95% confidence interval [CI], 1.3 to 5.8) and 2.9 (95% CI, 0.8 to 7.3), respectively.
-
Tenecteplase vs. Alteplase for Treatment of Acute Ischemic Stroke: It Is Time to Make the Change
Since 1996, when the U.S. Food and Drug Administration approved the use of intravenous alteplase for the treatment of acute ischemic stroke, there has been a steady increase in the adoption of both intravenous thrombolysis as well as endovascular thrombolysis and mechanical thrombectomy for the treatment of patients with acute ischemic stroke and large vessel occlusion. There now is extensive experience with the use of tenecteplase for the treatment of acute ischemic stroke. It has been shown to be equally efficacious, with a similar risk profile as alteplase.
-
Does Topiramate Decrease the Efficacy of Oral Contraceptives?
In this retrospective cohort study, women taking low-dose topiramate (< 200 mg per day) and oral contraception did not have more contraceptive failures compared to women taking other headache remedies (propanolol, metoprolol, amitriptyline, venlafaxine, or verapamil), with an adjusted rate difference of 0.00 (95% confidence interval, -0.3, 0.3).
-
Extended Use of Intrauterine Devices: New Data
In this prospective cohort study, 362 participants started year 6 of the device and 223 women completed eight years of 52-mg levonorgestrel intrauterine device use. For years 6-8, the three-year Pearl Index (95% confidence interval) was 0.28 (0.03-1.00), with a three-year cumulative failure rate of 0.68% (0.17-2.71).
-
HPV Vaccination in Adolescence Prevents Cancer More than 10 Years Later
In a study of human papillomavirus (HPV) vaccination, researchers evaluated cancer protection over up to 11 years of follow-up. During this time, the authors noted 100% vaccine efficacy at preventing HPV-associated cancers.
-
Greater Awareness of Reporting Bias on Antidepressants, Yet Problem Persists
An investigator who was part of a landmark study on the efficacy of antidepressants recently revisited reporting transparency in this area of research.
-
HPV Vaccination in Adolescence Prevents Cancer More than 10 Years Later
This long-term follow-up study of three cluster-randomized trials of human papillomavirus (HPV) vaccination evaluated cancer protection over up to 11 years of follow-up. During this time, 17 HPV-positive cancers were identified in the unvaccinated group, and 0 were identified in the vaccinated group, indicating 100% vaccine efficacy at preventing HPV-associated cancers.
-
Booster Doses Effective Against Omicron
While vaccination provides protection against infection with omicron variant of SARS-CoV-2, high level protection from a need for hospitalization requires a booster dose.